Sort
82,697 grants matching “vaccine development”
Novel nanovaccines against opioid use disorders
$1,553,762Chenming M Zhang · Virginia Polytechnic Inst And St Univ · UG3 · FY2020 · DA
Optimization Of HIV Specific Immune Responses In Vivo
$1,553,207Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses
$1,553,196Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
The MW Cancer Prevention Clinical Trials Network
$1,552,933Lisa M Barroilhet · University Of Wisconsin-Madison · UG1 · FY2024 · CA
Poxvirus Modulation of Immune Responses
$1,552,813Indiana Univ-Purdue Univ At Indianapolis · P01 · FY2005 · AI
Immunogen Design for Induction of HIV distal gp41 broadly neutralizing antibodies
$1,552,366S Munir Alam · Duke University · P01 · FY2021 · AI
DEVELOPMENT OF AN AIDS PROTOTYPE VACCINE USING SIV
$1,552,287University Of Pittsburgh At Pittsburgh · P01 · FY2001 · AI
Dissecting the mechanisms of HIV resistance in vivo to broadly neutralizing antibodies
$1,552,089Alon Herschhorn · University Of Minnesota · U01 · FY2023 · AI
Adjuvant Development in the context of a vaccine to protect against tuberculosis
$1,551,986Nikolai Petrovsky · Vaxine Pty Ltd · N01 · FY2022 · AI
Pathogenesis of Acute CNS infection and injury
$1,551,284Dorian McGavern · National Institute Of Neurological Disorders And Stroke · ZIA · FY2025 · NS
Cell Prep Core
$1,551,155John Wunderlich · Division Of Basic Sciences - Nci · ZIC · FY2009 · CA
HORMONAL CONTRACEPTON & RISK OF HIV ACQUISITION
$1,550,708Morrison Charles · Family Health International · N01 · FY2010 · HD
Georgetown University, Lombardi Cancer Center Support Grant Competitive Renewal
$1,550,495Louis M Weiner · Georgetown University · P30 · FY2011 · CA
Georgetown University, Lombardi Cancer Center Support Grant Competitive Renewal
$1,550,491Louis M Weiner · Georgetown University · P30 · FY2012 · CA
Identifying Asthma-causing RSV Strains and Elucidating the Mechanisms of RSV-mediated Asthma Development
$1,550,210Tina V Hartert · Vanderbilt University Medical Center · U19 · FY2020 · AI
Viral and Host Determinants of Infant and Childhood Allergy and Asthma
$1,550,210Ray Stokes Peebles · Vanderbilt University Medical Center · U19 · FY2020 · AI
Research to control and eliminate malaria in SE Asia and SW Pacific
$1,550,071James Walter Kazura · Case Western Reserve University · U19 · FY2015 · AI
Development of a COVID-19 Vaccine
$1,549,907Raymond Goodrich · Colorado State University · N01 · FY2021 · AI
Active Immune Therapy and HAART for HIV-1 Infection
$1,549,799University Of Pennsylvania · P01 · FY2003 · AI
Structure-Function Studies of the HIV-1 Envelope Glycoproteins
$1,549,551Paolo Lusso · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
$1,549,397Charles Bix Shoemaker · Tufts University Boston · R01 · FY2025 · AI
Development of therapeutic pan-Alphavirus human monoclonal antibodies
$1,549,212Michael S. Diamond · La Jolla Institute For Immunology · U19 · FY2019 · AI
Mucosal Immune Defense Mechanisms of the Urinary Bladder
$1,548,815Marco Colonna · Washington University · U01 · FY2019 · AI
Neutralizing Botulinum Neurotoxin with Human Antibodies
$1,548,781Rae Lyn Burke · Sri International · U01 · FY2007 · AI
Cell Interactions in Three Dimensional Tissue Culture
$1,548,559Leonid B. Margolis · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2010 · HD